Beneficial Roles of Histone Deacetylase Inhibitor Butyrate to Multiple Myeloma, Acute Leukemia and Acute Myeloid Leukemia: Case Reports

AKIRA YAGI, Megumi Hasegawa, Hiroyuki Abe


Multiple myeloma (MM) belongs to hematological malignancy that derives pro-survival/proliferative signals from the bone marrow niche, and its incidence is increasing worldwide. Butyrate, a well-known epigenetic histone deacetylase inhibitor, reduces the viability of MM cells, induces MM cell apoptosis via transcriptional activation of p21. Inpresent review we discuss butyrate as a potential therapeutic drug for MM and case reports of MM, acute leukemia, malignant lymphoma and glioma patients.


Histone deacetylase inhibitor butyrate; Multiple myeloma; Hematological malignancy; Case reports; Aloe vera adjuvant

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.